Calamos Advisors LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is and the CUSIP is 40637HAB5. A total of 15 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Calamos Advisors LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q2 2022$18,996,000
+8.9%
10,000,0000.0%0.08%
+26.2%
Q1 2022$17,436,000
-0.7%
10,000,0000.0%0.06%
-1.5%
Q4 2021$17,559,000
-1.5%
10,000,0000.0%0.07%
-15.4%
Q3 2021$17,822,000
-8.9%
10,000,0000.0%0.08%
-12.4%
Q2 2021$19,564,000
+6.4%
10,000,0000.0%0.09%
-11.0%
Q1 2021$18,389,00010,000,0000.10%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2021
NameSharesValueWeighting ↓
WOLVERINE ASSET MANAGEMENT LLC 33,153,000$64,904,0000.49%
TENOR CAPITAL MANAGEMENT Co., L.P. 11,250,000$22,065,0000.48%
SSI INVESTMENT MANAGEMENT LLC 3,573,000$6,973,0000.45%
MIZUHO SECURITIES USA LLC 1,300,000$2,542,0000.21%
LINDEN ADVISORS LP 10,703,000$20,965,0000.11%
Calamos Advisors LLC 10,000,000$19,564,0000.09%
PALISADE CAPITAL MANAGEMENT, LP 2,000,000$3,915,0000.09%
BNP PARIBAS FINANCIAL MARKETS 3,294,000$6,460,344,0000.01%
Kohlberg Kravis Roberts & Co. L.P. 1,000,000$1,956,0000.01%
D. E. Shaw & Co., Inc. 4,000,000$7,824,0000.01%
View complete list of HALOZYME THERAPEUTICS INC shareholders